Vancomycin

Name: Vancomycin
Brand: Nova Science Publishers Inc
SKU: 9781629485591
Price: 837.33 RON
Availability: InStock

Biosynthesis, Clinical Uses & Adverse Effects

Autor: Abu Gafar Hossion

Limbă:

Legare: Copertă tare

Editura: Nova Science Publishers Inc

Disponibilitate: șansă 50%

Şanse de a obține acest titlu

837.33 lei

There have been news reports with the tales of many community acquired bacterial infections that lea...

Informații despre carte

Autor

Abu Gafar Hossion

Limbă

engleză

Legare

Carte - Copertă tare

Publicat

2014

Pagini

123

EAN

9781629485591

ISBN

9781629485591

Enbook ID

06441683

Editura

Nova Science Publishers Inc

Greutate

372

Dimensiuni

158 x 234 x 15

Descriere completă

There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalisation. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty regarding optimal laboratory tests and the clinical relevance of reduced vancomycin susceptibility in S. aureus; changes in the Clinical and Laboratory Standards Institute (CLSI) breakpoints for vancomycin against S. aureus; and increasing concern regarding the efficacy of vancomycin for the treatment of infection due to gram-positive bacteria, such as S. aureous. Vancomycin can be administered either intravenously or orally, but in order to treat systemic infections, vancomycin must be administered intravenously. Identifying the changes in genome content or expression, which are associated with the acquisition of the different types of vancomycin resistance, is an important step in the process of understanding the molecular basis of resistance with the potential to provide leads both for new drug targets and diagnostic biomarkers. However, considering that vancomycin has a slow bactericidal activity, clinicians have to adequately prescribe vancomycin to avoid the acquisition of resistance under therapy and to facilitate the cure.

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Cele mai căutate

Categories

Authors

Publishers

Produse

Produse

Vancomycin

Biosynthesis, Clinical Uses & Adverse Effects

Informații despre carte

Descriere completă

S-ar putea să te intereseze

Clienții care au cumpărat această carte au mai cumpărat și